Olumiant and Pancytopenia - a phase IV clinical study of FDA data

Summary:

Pancytopenia is reported as a side effect among people who take Olumiant (baricitinib), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Amlodipine, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Pancytopenia when taking Olumiant. It is created by eHealthMe based on reports of 5,692 people who have side effects when taking Olumiant from the FDA, and is updated regularly.

What is Olumiant?

Olumiant has active ingredients of baricitinib. eHealthMe is studying from 5,698 Olumiant users. Check the latest studies of Olumiant.

What is Pancytopenia?

Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets) is found to be associated with 1,793 drugs and 2,430 conditions by eHealthMe. Check the latest studies of Pancytopenia.

On Jul, 08, 2026

5,692 people reported to have side effects when taking Olumiant.
Among them, 18 people (0.32%) have Pancytopenia.

Among these 18 people:

How long have people been on Olumiant when they have Pancytopenia? *

What is the gender of people who have Pancytopenia when taking Olumiant? *

female: 61.11 %
male: 38.89 %

What is the age of people who have Pancytopenia when taking Olumiant? *

What are other drugs people take besides Olumiant? *

What are other side effects people have besides Pancytopenia? *

Febrile Neutropenia (fever with reduced white blood cells): 2 people, 11.11%
Wound Abscess (pus in wound): 1 person, 5.56%
Hepatic Lesion: 1 person, 5.56%
Hepatic Cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue): 1 person, 5.56%
Heparin-Induced Thrombocytopenia: 1 person, 5.56%
Haemorrhage (bleeding): 1 person, 5.56%
Haematoma (collection of blood outside the blood vessels): 1 person, 5.56%
H1n1 Influenza (flu (influenza), which is caused by virus influenza a (h1n1)): 1 person, 5.56%
Femoral Neck Fracture (neck of femur bone fracture): 1 person, 5.56%
Drowsiness: 1 person, 5.56%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 9 people, 50.00%
Tumor Necrosis Factor Receptor-Associated Periodic Syndrome: 1 person, 5.56%
Osteoporosis (bones weak and more likely to break): 1 person, 5.56%
Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Olumiant and have Pancytopenia?

- Check whether Pancytopenia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Olumiant:

Olumiant (5,698 reports)

Pancytopenia treatments and more:

Pancytopenia (69,290 reports)

Browse all side effects of Olumiant:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pancytopenia:

Pancytopenia (1,793 drugs)

Browse all the conditions that are associated with Pancytopenia:

Pancytopenia (2,430 conditions)

Related publications that referenced our studies

Ate? ?, Arikan MF, Kaplan M, Altay M, "Hydroxyzine induced pancytopenia and petechial rashes: a rare complication", Journal Of Contemporary Medicine, 2017 Jan .
Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M, "Pancytopen? a and Seps? s due to Meropenem: A Case Report", Tropical Journal of Pharmaceutical Research, 2013 Jan .
Ate? ?, Arikan MF, Kaplan M, Altay M, "Hydroxyzine induced pancytopenia and petechial rashes: a rare complication", Journal Of Contemporary Medicine, 2017 Jan .
Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M, "Pancytopen? a and Seps? s due to Meropenem: A Case Report", Tropical Journal of Pharmaceutical Research, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on baricitinib (the active ingredients of Olumiant) and Olumiant (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.